Orchard Therapeutics, a UK-based gene therapy spinout of University College London, closed a $150m oversubscribed series C round featuring medical marketing group Medison and healthcare management services provider Sphera Global Health Care on Monday. The round was led by Deerfield Management. Medison participated through its strategic investment vehicle, Medison Ventures. Temasek, the Singaporean state-owned investment…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.